3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
6
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Salivary Gland Neoplasms
3
Radiation Injuries
3
Carcinoma, Hepatocellular
3
Testicular Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Laryngeal Neoplasms
2
Esthesioneuroblastoma, Olfactory
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Medullary
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Testicular Germ Cell Tumor
1
Stomatitis
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Mouth Neoplasms
1
Interventions
pembrolizumab
31
Nivolumab
11
Ipilimumab
6
spartalizumab
5
cemiplimab
5
atezolizumab
5
Gemcitabine
4
Docetaxel
4
durvalumab
3
budigalimab
3
avelumab
3
Oxaliplatin
3
Leucovorin
3
Irinotecan
3
Immune Checkpoint Inhibitors
3
Fluorouracil
3
Cyclophosphamide
3
Cetuximab
3
Carboplatin
3
130-nm albumin-bound paclitaxel
3
obinutuzumab
2
lenvatinib
2
fludarabine
2
epacadostat
2
X-Rays
2
Paclitaxel
2
Immunoglobulin G
2
Cisplatin
2
Capecitabine
2
Biopsy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
sargramostim
×
Head & Neck
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled